Vomaris patent estate grows to six issued U.S. patents and three granted international patents with U.S. Pat. No. 8,224,439

CHANDLER, Ariz., July 17, 2012 /PRNewswire/ -- Vomaris Innovations, Inc., a leading regenerative medicine company focusing on wound care with bioelectric technology, has been granted another patent (U.S. Pat. No. 8,224,439) related to its bioelectric technology surrounding the use of devices that rely upon reducing and oxidizing agents to treat biologic tissue and promote healing.

"Our growing and valuable patent estate is indicative of the powerful momentum behind our leading bioelectric technology," said Michael P. Nagel, Vomaris President and CEO.

"Procellera® is transforming the way wounds are managed," he added, "which will create meaningful cost savings while enhancing the quality of patient care worldwide."

Procellera® is the first totally self-contained, conformable, cut-to-fit, electrically active wound dressing in the world. The technology is extremely versatile and scalable and spans multiple healthcare industries.

For more information about Procellera®, please visit www.vomaris.com.

About Vomaris Innovations, Inc.
Vomaris Innovations, Inc., based in Chandler, Arizona, is a regenerative medical device company specializing in emerging bioelectrical field generating innovative technologies for the wound care market. FDA cleared, Procellera® Wound Dressing is the world's first wireless, self-contained antimicrobial wound dressing that generates a sustained electrical microcurrent at its surface when activated with a conductive fluid. Procellera® is indicated for professional use for partial and full-thickness wounds such as pressure ulcers, venous ulcers, diabetic ulcers, burns, surgical incisions, and donor/recipient graft sites.  Randomized clinical trials are in process looking at other possible wound healing benefits for the use of Procellera®.  For more information, visit www.vomaris.com or call 480.921.4948.

SOURCE Vomaris Innovations, Inc.